Barclays PLC Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Barclays PLC boosted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS) by 1,813.4% during the third quarter, Holdings Channel reports. The institutional investor owned 7,596 shares of the company’s stock after buying an additional 7,199 shares during the period. Barclays PLC’s holdings in NewAmsterdam Pharma were worth $126,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quarry LP raised its holdings in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the period. Bellevue Group AG purchased a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at about $128,000. XTX Topco Ltd acquired a new position in shares of NewAmsterdam Pharma during the third quarter worth $187,000. M&T Bank Corp grew its holdings in NewAmsterdam Pharma by 54.1% during the 3rd quarter. M&T Bank Corp now owns 27,328 shares of the company’s stock valued at $454,000 after purchasing an additional 9,593 shares in the last quarter. Finally, Sei Investments Co. increased its stake in NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after buying an additional 8,087 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $23.20 on Friday. The business has a 50 day moving average of $23.58 and a two-hundred day moving average of $19.91. NewAmsterdam Pharma has a 52 week low of $15.19 and a 52 week high of $27.29.

Wall Street Analyst Weigh In

Several research analysts recently commented on NAMS shares. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. HC Wainwright reissued a “buy” rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, Scotiabank upped their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $39.80.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now owns 11,778,760 shares in the company, valued at approximately $295,411,300.80. This represents a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 446,730 shares of company stock worth $11,438,695 in the last 90 days. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.